Navigation Links
XTENT to Present at Cowen and Company's 28th Annual Health Care Conference
Date:3/12/2008

MENLO PARK, Calif., March 12 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that Gregory D. Casciaro, President and Chief Executive Officer, will present at Cowen and Company's 28th Annual Health Care Conference on Tuesday, March 18, 2008 at 9:30 a.m. Eastern. This event will be held at the Boston Marriot Copley Place in Boston, MA.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT Custom NX DES Systems have not been approved for sale by any regulatory authority.

Information about XTENT is available at our website at http://www.xtentinc.com.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. XTENT Announces 2007 Financial Results
2. New study shows extent of harmful human influences on global ecosystems
3. XTENT Announces 2007 Financial Results Conference Call
4. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
5. XTENT Announces Third Quarter 2007 Financial Results
6. MedCath Corporation to Present at the Citi 2008 Small and Mid-Cap Conference
7. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Lehman Brothers Global Healthcare Conference
9. Zimmer Holdings to Present at Upcoming Investor Conferences
10. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
11. Edwards Lifesciences to Present at the Cowen and Company Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...ia Medical School presented their study that shows...tic neuropathy, or nerve damage.Topiramate (Topama...t research shows it can also promote significant w...2 diabetes, the drug showed evidence of improving ...
...p the hearts of children with diabetes. Researcher...indings over the weekend at the American Diabetes ...ding to the American Diabetes Association, people ...likely to have heart disease as compared to those ...
...s to numerous health concerns. But a new study fin...ink weight to athletic performance and appearance ...s also fail to see the importance of a healthy wei...n children more in terms of appearance and self-es...
... can have a serious impact on their health and qua... Educators (AADE) says about a third of the estima...sis, the most common type of nail fungus. Because ...ced ability to fight infection, people with diabet...
Other Medicine News:
(Date:10/9/2008)... World Sight Day 2008 focuses on the need to ...ct. 9 /- Of the 45 million people wor...and three-quarters of them could,have avoided thei...,treated., To view the Multimedia News Release, g..., Alcon, the world,s leader in eye care products ...
(Date:10/9/2008)... Top Line Clinical Results Expected in Novemb...Call/ -- SCOLR Pharma, Inc.,(Amex: DDD ) announce...osing,for the third of its three pivotal trials to...on of 12-hour extended-release (ER) ibuprofen for,...ects to report top-line,results from this pivotal ...
(Date:10/9/2008)... STOCKHOLM, October 9 /PRNewswire-FirstCall/ ...fluential medical journal, the New England Journal...s from the company,s study,of the Diamyd(R) diabet...ww.newscom.com/cgi-bin/prnh/20080314/297194 ), T...ite,( http://www.nejm.org ) and will be in print o...
(Date:10/8/2008)... Acceptance Will Reduce Animal Use in Cosmeti.../- MatTek Corp. today announced,that ...lti-laboratory,"catch-up" validation study on MatT.... The test results demonstrated the required sensi...as a validated alternative to animal,testing for d...
Breaking Medicine Technology:ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Reclast 28R 29 Receives US FDA Approval as First and Only Once Yearly Treatment for Women With Postmenopausal Osteoporosis 1 1Reclast 28R 29 Receives US FDA Approval as First and Only Once Yearly Treatment for Women With Postmenopausal Osteoporosis 1 2Reclast 28R 29 Receives US FDA Approval as First and Only Once Yearly Treatment for Women With Postmenopausal Osteoporosis 1 3Reclast 28R 29 Receives US FDA Approval as First and Only Once Yearly Treatment for Women With Postmenopausal Osteoporosis 1 4Reclast 28R 29 Receives US FDA Approval as First and Only Once Yearly Treatment for Women With Postmenopausal Osteoporosis 1 5Reclast 28R 29 Receives US FDA Approval as First and Only Once Yearly Treatment for Women With Postmenopausal Osteoporosis 1 6Muscle mass 3A Scientists identify novel mode of transcriptional regulation during myogenesis 92 1A new radiation therapy treatment developed for head and neck cancer patients 87 1A new radiation therapy treatment developed for head and neck cancer patients 87 2Scientists retrace evolution with first atomic structure of an ancient protein 82 1Scientists retrace evolution with first atomic structure of an ancient protein 82 2Scientists retrace evolution with first atomic structure of an ancient protein 82 3
...ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 1, 2007 ...nced that data on the,long-term safety of the inve...inidine) and the prevalence of Involuntary,Emotion... during a,poster session at the American Academy o...he information was presented in the,following post...
...Drugs Might Increase Risk of Tumor Growth, Data Su...- Echoing recent FDA,warnings, a research group fr...ve use of a group of drugs called,"erythropoiesis-...,cancer patients, according to a commentary in the...Med Press. , The article by Dr. Terence R. Lappin ...
Other Medicine Technology:Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia,Long-Term Safety Data at AAN Annual Meeting 2Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia,Long-Term Safety Data at AAN Annual Meeting 3Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia,Long-Term Safety Data at AAN Annual Meeting 4Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia,Long-Term Safety Data at AAN Annual Meeting 5Researchers Urge Caution in Using ESAs for Cancer-Related Anemia 2Researchers Urge Caution in Using ESAs for Cancer-Related Anemia 3
...the rapid, detection of platelet dysfunction. It i... that uniquely simulates the in vivo function of p...s platelet function under high shear conditions si...lood vessel. Testing is performed using a small wh...
...rming erythrocyte sedimentation rate (ESR) tests u...es-matic System DIESSE brings to the clinical diag... which addresses and resolves every technical limi...e.,By means of a fully automated analyzer and a es...
...n rate analysers, which are especially user-friend...stablished advantages of the existing analysers wi...rantee time-saving standardised analysis of the er...s an essential aspect of daily recurrent routine a...
Blood sedimentation rate analysis
Medicine Products: